Evaluation of the metabolism of high energy phosphates in patients with Chagas' disease;Avaliação do metabolismo dos fosfatos de alta energia em pacientes com doença de Chagas

Arquivos Brasileiros de Cardiologia

Volumn 95, Issue 2, 2010, Pages 264-271

  Leme, Ana Maria Betim Paes ^a   Salemi, Vera Maria Cury ^a   Parga, José Rodrigues ^a   Ianni, Bárbara Maria ^a   Mady, Charles ^a   Weiss, Robert G ^b   Kalil Filho, Roberto ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chagas cardiomyopathy; Chagas' disease; Energy metabolism

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATINE PHOSPHATE; PHOSPHATE; PHOSPHORUS 31;

ADULT; AGED; ARTICLE; CHAGAS DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE METABOLISM; HEART VENTRICLE FUNCTION; HIGH ENERGY PHOSPHATE; HUMAN; MALE; METABOLIC PARAMETERS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PHOSPHATE METABOLISM; PHOSPHOCREATINE BETA ADENOSINE TRIPHOSPHATE RATIO; PROSPECTIVE STUDY; REST; THORAX RADIOGRAPHY;

EID: 77957321631     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2010005000099     Document Type: Article

References (33)

1. Bern C, Montgomery SP, Herwaldt BL, Rassi A Jr, Marin-Neto JA, Dantas RO, et al. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA. 2007; 298 (18): 2171-81. (Pubitemid 350106656)
2. Mady C, Ianni BM, Arteaga E, Salemi VM, Frimm CC. Maximal functional capacity in patients with Chagas' cardiomyopathy without congestive heart failure. J Card Fail. 2000; 6 (3): 220-4.
3. Higuchi ML. Chronic chagasic cardiopathy: the product of a turbulent hostparasite relationship. Rev Inst Med Trop S Paulo. 1997; 39: 53-60.
4. Marin-Neto JA. Cardiac dysautonomia and pathogenesis of Chagas' heart disease. Int J Cardiol. 1998; 66 (2): 129-31.
5. Rossi MA. Microvascular changes as a cause of chronic cardiomyopathy in Chagas' disease. Am Heart J. 1990; 120 (1): 233-6.
6. Rossi MA. The pattern of myocardial fibrosis in chronic Chagas' heart disease. Int J Cardiol. 1991; 30 (1): 335-40.
7. Marin-Neto JA, Marzullo P, Marcassa C, Gallo L, Maciel BC, Bellina R, et al. Myocardial perfusion defects in chronic Chagas' disease as detected by thallium-201 scintigraphy. Am J Cardiol. 1992; 69 (8): 780-4.
8. Acquatella H, Pérez JE, Condado JA, Sanchez I. Limited myocardial contractile reserve and chronotropic incompetence in patients with chronic Chagas' disease. assessment by dobutamine stress echocardiography. J Am Coll Cardiol. 1999; 33 (2): 522-9.
9. Tanowitz HB, Kaul DK, Chen B, Morris SA, Factor SM, Weiss LM, et al. Compromised microcirculation in acute murine Trypanosoma cruzi infection. J Parasitol. 1996; 82 (1): 124-30.
10. Tanowitz HB, Burns ER, Sinha AK, Kahn NN, Morris SA, Factor SM, et al. Enhanced platelet adherence and aggregation in Chagas' disease: a potential pathogenic mechanism for cardiomyopathy. Am J Trop Med Hyg. 1990; 43 (3): 274-81.
11. Ingwall JS. Is cardiac failure a consequence of decreased energy reserve? Circulation. 1993; 87: VII-58-VII-62.
12. Kalil Fillho R, De Albuquerque CP, Weiss RG, Mocelim A, Bellotti G, Cerri G, Pileggi F. Normal high energy phosphate ratios in "stunned" human myocardium. J Am Coll Cardiol. 1997; 30 (5): 1228-32.
13. Ten Hove M, Neubauer S. MR spectroscopy in heart failure - clinical and experimental findings. Heart Fail Rev. 2007; 12 (1): 48-57. (Pubitemid 46629246)
14. Hudsmith LE, Neubauer S. Detection of myocardial disorders by magnetic resonance spectroscopy. Nat Clin Pract Cardiovasc Med. 2008; 5 (Suppl 2): S49-56.
15. Lamb HJ, van der Meer RW, de Roos A, Bax JJ. Cardiovascular molecular MR imaging. Eur J Nucl Med Mol Imaging. 2007; 34 (Suppl 1): S99-104.
16. Camargo ME, Oshino-Shimizu S, Macedo V, Peres BA, Castro C. Diagnóstico sorológico da infecção humana pelo Trypanosoma cruzi. Estudo comparativo de testes de fixação do complemento, imunofluorescência, hemaglutinação e floculação em 3.624 soros. Rev Inst Med Trop São Paulo. 1977; 19: 254-60.
17. Moffa PJ, Sanches PCR. Eletrocardiograma: normal e patológico. São Paulo: Editora Roca; 2001.
18. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440-63.
19. Sardanelli F, Quarenghi M. MR spectroscopy of the heart. Radiol Med. 2006; 111 (8): 1025-34.
20. Dawson J, Gadian DG, Wilkie DR. Proceedings: living muscle studied by 31P nuclear magnetic resonance. J Physiol. 1976; 258 (2): 82P-83P.
21. Ordidge RJ, Connelly A, Lohman JAB. Image-selected in vivo spectroscopy (ISIS): a new technique for spatially selective NMR spectroscopy. J Magn Reson. 1985; 66: 283-94.
22. Bottomley PA. Noninvasive study of high-energy phosphate metabolism in human heart by depth-resolved 31P NMR spectroscopy. Science. 1985; 229 (4715): 769-72.
23. Beer M. Cardiac spectroscopy: techniques, indications and clinical results. Eur Radiol. 2004; 14 (6): 1034-47.
24. Tyler DJ, Hudsmith LE, Clarke K, Neubauer S, Robson MD. A comparison of cardiac (31) P MRS at 1.5 and 3 T. NMR Biomed. 2008; 21 (8): 793-8.
25. Neubauer S, Krahe T, Schindler R. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease: altered cardiac high-energy phosphate metabolism in heart failure. Circulation. 1992; 86 (6): 1810-8.
26. Neubauer S, Horn M, Pabst T, Gödde M, Lübke D, Jilling B, et al. Contributions of 31P-magnetic resonance spectroscopy to the understanding of dilated heart muscle disease. Eur Heart J. 1995; 16 (Suppl O): 115-8.
27. Bottomley PA. MR spectroscopy of the human heart: the status and the challenges. Radiology. 1994; 191 (3): 593-612.
28. Klug G, Wolf C, Trieb T, Frick M, Koehler A, Schocke MF, et al. Evaluation of transient apical ballooning with cardiac magnetic resonance imaging and 31-phosphorous magnetic resonance spectroscopy. Int J Cardiol. 2007; 118 (2): 249-52.
29. Hansch A, Rzanny R, Heyne JP, Leder U, Reichenbach JR, Kaiser WA. Noninvasive measurements of cardiac high-energy phosphate metabolites in dilated cardiomyopathy by using 31P spectroscopic chemical shift imaging. Eur Radiol. 2005; 15 (2): 319-23.
30. Hardy CJ, Weiss RG, Bottomley PA, Gerstenblith G. Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J. 1991; 122 (3 Pt 1): 795-801.
31. Schaefer S, Gober JR, Schwartz GG, Twieg DB, Weiner MW, Massie B. In vivo phosphorus-31 spectroscopy imaging in patients with global myocardial disease. Am J Cardiol. 1990; 65 (16): 1154-61.
32. Carrasco-Guerra HA, Palacios-Pru E, Dagert de Scorza C, Molina C, Inglessis G, Mendoza RVB. Clinical, histochemical and ultrastructural correlation in septal endomyocardial biopsies from chronic chagasic patients: detection of early myocardial damage. Am. Heart J. 1987; 113 (3): 716-24.
33. Higuchi ML, Fukasawa S, De Brito T, Parzianello LC, Bellotti G, Ramires JA. Different microcirculatory and interstitial matrix patterns in idiopathic dilated cardiomyopathy and Chagas' disease: a three dimensional confocal microscopy study. Heart. 1999; 82 (3): 279-85. (Pubitemid 29429598)